Caris Q2 2026 earnings: Molecular profiling drives 45% revenue growth

Caris Life Sciences (Nasdaq: CAI) reported Q2 2026 revenue of $263.7 million, up 45% from $181.4 million, while diluted net loss per share attributable to common shareholders improved to $0.00 from a loss of $7.97. Molecular profiling volume and higher average selling prices drove revenue growth, helping gross margin expand and bringing the GAAP net loss close to break-even.

Core financial results

Revenue increased by $82.3 million year over year, while gross profit grew faster than operating expenses. Caris consequently moved from an operating loss to operating income, although other expenses prevented the company from reporting positive GAAP net income.

Adjusted EBITDA and operating cash flow also improved, but these measures should be viewed separately from the near-break-even GAAP result.

The prior-year per-share result also reflected preferred-stock deemed dividends and redemption-value adjustments. As a result, the EPS improvement was substantially larger than the change in GAAP net loss alone.

Business and segment performance

Molecular profiling services accounted for about 96% of quarterly revenue and generated all of the company’s overall growth. Pharma research and development services moved in the opposite direction, indicating that the quarter’s performance was increasingly concentrated in the core profiling business.

Clinical volume included approximately 48,300 MI Profile cases and 10,700 Caris Assure cases. Caris said both higher case volume and improved average selling prices contributed to profiling revenue growth. Total clinical cases also increased by more than 12% sequentially, according to management.

Caris launched its Detect multi-cancer early detection test during the period. It also launched ChromoSeq after receiving MolDX approval and introduced the MI Clarity prognostic tool, although the release did not quantify revenue contributions from these products.

Revenue growth outpaced operating costs, but other expenses prevented GAAP profitability

Operating expenses rose 16% to $152.7 million, considerably slower than the 45% increase in revenue. Caris attributed the expense growth primarily to headcount-related costs. Combined with the five-percentage-point gross-margin expansion, this operating leverage produced $26.9 million of operating income compared with an $18.0 million loss one year earlier.

However, $27.5 million of total other expense nearly offset the operating profit. This included $25.1 million of other expense and $9.2 million of interest expense, partially offset by $6.8 million of interest income. Caris therefore remained slightly loss-making under GAAP despite reporting $55.7 million of adjusted EBITDA. The adjusted measure excluded items including other expense, interest, depreciation and amortization, and $22.2 million of stock-based compensation.

Cash generation improved as investment spending accelerated

Quarterly operating cash flow increased to $28.5 million, supported by improved clinical volume and average selling prices. Free cash flow rose only modestly to $6.4 million because capitalized software and purchases of property and equipment increased to $22.1 million from $1.4 million a year earlier.

At June 30, 2026, the balance sheet reported $690.9 million of cash, cash equivalents and restricted cash, along with $102.2 million of short-term marketable securities. Total current and long-term indebtedness was approximately $393.2 million. Supplies increased to $123.8 million from $63.6 million at the end of 2025, making inventory-related investment an important working-capital item to monitor.

Caris also had approximately $82.1 million remaining under its board-authorized share repurchase program of up to $100 million. The announcement did not characterize the authorization as an assessment of the company’s valuation.

2026 guidance

Caris raised its full-year revenue outlook to $1.03 billion-$1.04 billion, representing expected growth of 27%-28% from 2025. The previous revenue range was not included in the release, so the size of the increase cannot be determined from the provided information. The company also reaffirmed its clinical therapy selection volume-growth target.

The full-year revenue growth range remains below Q2’s 45% rate, meaning the updated outlook does not assume that the quarter’s pace will continue throughout the year.

Management perspective

Founder, Chairman and CEO David Dean Halbert attributed the record clinical case volume to sustained demand and investment in Caris’ commercial organization. Management is also positioning the company’s large molecular-profile database and AI capabilities as the foundation for expanding beyond therapy selection into early cancer detection and intervention, with Caris Detect serving as the principal new initiative discussed in the release.

Risks investors should monitor

• Dependence on molecular profiling: Approximately 96% of quarterly revenue came from molecular profiling services. Slower clinical volume or weaker average selling prices would have an outsized effect on company-wide growth.
• Payer coverage and reimbursement: ASP improvement contributed to Q2 growth, while Caris identifies third-party reimbursement and coverage decisions as business risks. Unfavorable decisions could pressure revenue and margins.
• Uneven service-line performance: Pharma R&D services revenue declined by about 38%, leaving overall growth less diversified across the company’s two reported revenue streams.
• Other expenses and debt costs: Caris generated operating income but remained slightly unprofitable after $27.5 million of other expense. Persistent interest and other charges could continue to separate operating performance from GAAP net income.
• Execution on new products: Caris Detect, ChromoSeq and MI Clarity broaden the product portfolio, but their commercial adoption, regulatory requirements and contribution to future revenue were not quantified.

Summary

Caris’ Q2 2026 results showed meaningful operating leverage as molecular profiling volume and pricing gains lifted revenue faster than costs. Gross-margin expansion, positive operating income and stronger cash generation marked progress toward sustainable profitability, although other expenses still kept GAAP earnings just below break-even. Future results will depend on maintaining profiling demand and pricing, converting new products into measurable revenue, and delivering the increased full-year outlook.